Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
Maria Elisa Mancuso, Aaron Lubetsky, Brigitte Pan‐Petesch, Toshko Lissitchkov, Azusa Nagao, Wilfried Seifert, Yanyan Li, Elena Santagostino
Topics & Concepts
RegimenMedicineDosingAdverse effectSurgeryInternal medicineHemophilia Treatment and ResearchPlatelet Disorders and Treatments